ProShares Trust - ProShares UltraPro Short S&P 500
SPXU
Get informed when a big investor buys or sells
+ FollowMarket Cap$37.19B
Close$
Share Statistics
| Market cap | $37.19 Billion |
|---|---|
| Enterprise Value | $37.01 Billion |
| Dividend Yield | $2.53 (6.71%) |
| Earnings per Share | $- |
| Beta | -2.75 |
| Outstanding Shares | - |
Return
| Return on Equity | -25.93% |
|---|---|
| Return on Assets | -23.92% |
| Return on Invested Capital | -27.36% |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 2834.16 |
| Enterprise Value to EBIT | -492.37 |
| Enterprise Value to Net Income | -525 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.04 |
Revenue Sources
No data
Insider Trades
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 1.0461▼ 15.43% |
|---|---|
| Total Calls | 1,769,025▲ 50.67% |
| Total Puts | 1,850,625▲ 31.30% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 10.19%▲ 4.72% |
|---|---|
| Total Invested | $67.61M▲ 189.88% |
| Investors Holding | 49▲ 8.00% |
ESG Score
No data
About BioAge Labs, Inc.
62 employees
CEO: Dr. Kristen Fortney Ph.D. BioAge Labs, Inc. is a clinical-stage biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets allows users to identify targets bas...